More languages
More actions
(→Off-label marketing of Zyprexa: Elaboration.) |
m (→Controversies: Fix typo in News title.) |
||
| Line 27: | Line 27: | ||
===Unapproved promotion of Zyprexa=== | ===Unapproved promotion of Zyprexa=== | ||
Between 1999 and 2005, Eli Lilly promoted Zyprexa in primary-care for treatment of Dementia and Alzheimer's Dementia, without the approval of the [[Food and Drug Administration]].<ref name=:0>{{News citation|title=Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve | Between 1999 and 2005, Eli Lilly promoted Zyprexa in primary-care for treatment of Dementia and Alzheimer's Dementia, without the approval of the [[Food and Drug Administration]].<ref name=:0>{{News citation|title=Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations <nowiki>[of]</nowiki> Off-label Promotion of Zyprexa|url=https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa|date=2009-01-15|newspaper=Office of Public Affairs}}</ref> | ||
In 2007, Eli Lilly had been sued by the [[United States of America|U.S government]], for $1.415 billion, due to the unapproved promotion of Zyprexa in primary-care.<ref name=:0 /> | In 2007, Eli Lilly had been sued by the [[United States of America|U.S government]], for $1.415 billion, due to the unapproved promotion of Zyprexa in primary-care.<ref name=:0 /> | ||
Revision as of 13:36, 12 September 2022
Eli Lilly and Company | |
|---|---|
 | |
| Industry | Pharmacy |
| Founder | Eli Lilly |
| Key people | David A. Ricks (Chairperson, President, & CEO) Anat Ashkenazi (Vice president & CFO)[1] |
| Ownership | Lilly Endowment, 11.6%[2] |
| Revenue | +US$22.319 billion (2019)[3] |
| Net income | +US$8.318 (2019)[3] |
| Total assets | -US$39.286 (2019)[3] |
| Website | |
| www.lilly.com | |
Eli Lilly and Company, often shortened to Eli Lilly, is a U.S-based pharmaceutical corporation.
Controversies
Prozac Jury corruption
On July 20, 2019; Eli Lilly was found to have bribed the Jury and victims of mass shootings 20 million dollars, in multiple lawsuits against Eli Lily for murder from Prozac, to hide evidence of Prozac increasing the rate of mass shootings.[4]
Unapproved promotion of Zyprexa
Between 1999 and 2005, Eli Lilly promoted Zyprexa in primary-care for treatment of Dementia and Alzheimer's Dementia, without the approval of the Food and Drug Administration.[5]
In 2007, Eli Lilly had been sued by the U.S government, for $1.415 billion, due to the unapproved promotion of Zyprexa in primary-care.[5]
References
- ↑ Jaimy Lee (9 February 2021). Lilly promotes Anat Ashkenazi to CFO, says previous CFO had 'inappropriate' communication with employees Market Watch. Archived from the original on 9 February 2021.
- ↑ Document.
- ↑ 3.0 3.1 3.2 Eli Lilly and Company 2019 Annual Report (19 February 2020).
- ↑ Andrew Wolfson (2019-09-12T12:33Z−07:00). "Prozac maker paid millions to secure favorable verdict in mass shooting lawsuit, victims say"
- ↑ 5.0 5.1 "Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations [of] Off-label Promotion of Zyprexa" (2009-01-15). Office of Public Affairs.